Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We employ our advanced, specialised process to create targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q16549

UPID:
PCSK7_HUMAN

ALTERNATIVE NAMES:
Lymphoma proprotein convertase; Prohormone convertase 7; Proprotein convertase 7; Proprotein convertase 8; Subtilisin/kexin-like protease PC7

ALTERNATIVE UPACC:
Q16549; B0YJ60; Q3C1X1; Q53GM4; Q96FK8; Q9UL57

BACKGROUND:
The enzyme Proprotein convertase subtilisin/kexin type 7, known by alternative names such as Lymphoma proprotein convertase and Proprotein convertase 8, is a serine endoprotease. This enzyme is critical for the cleavage of proproteins at paired basic amino acids, adhering to the RXXX[KR]R consensus motif. Its function is primarily associated with the constitutive secretory pathway, highlighting its importance in the post-translational modification of proteins.

THERAPEUTIC SIGNIFICANCE:
The exploration of Proprotein convertase subtilisin/kexin type 7's function offers a promising pathway to uncovering novel therapeutic strategies. Its key role in proprotein processing underscores its potential as a target for intervention in disease mechanisms.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.